We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byTalon Shugar
Modified over 2 years ago
Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients by Betty Y. Chang, Michelle Francesco, Martin F. M. De Rooij, Padmaja Magadala, Susanne M. Steggerda, Min Mei Huang, Annemieke Kuil, Sarah E. M. Herman, Stella Chang, Steven T. Pals, Wyndham Wilson, Adrian Wiestner, Marcel Spaargaren, Joseph J. Buggy, and Laurence Elias Blood Volume 122(14):2412-2424 October 3, 2013 ©2013 by American Society of Hematology
Transient mobilization of lymphocytes in MCL patients treated with ibrutinib. Chang B Y et al. Blood 2013;122:2412-2424 ©2013 by American Society of Hematology
CD19+CD5+ cells have decreased CXCR4, CD38, and Ki67 expression following ibrutinib treatment. Chang B Y et al. Blood 2013;122:2412-2424 ©2013 by American Society of Hematology
Ibrutinib inhibits migration of MCL cells beneath stromal cells (pseudo-emperipoiesis) and the formation of CXCL12-stimulated cortical actin. Chang B Y et al. Blood 2013;122:2412-2424 ©2013 by American Society of Hematology
Ibrutinib suppresses BCR- and coculture-stimulated signaling and cytokine and chemokine production of MCL cells. Chang B Y et al. Blood 2013;122:2412-2424 ©2013 by American Society of Hematology
Ibrutinib inhibits BCR-activated adhesion of MCL cells. Chang B Y et al. Blood 2013;122:2412-2424 ©2013 by American Society of Hematology
Ibrutinib inhibits CXCL12-/CXCL13-activated adhesion and migration of MCL cells. Chang B Y et al. Blood 2013;122:2412-2424 ©2013 by American Society of Hematology
Ibrutinib inhibits BCR- and chemokine-induced adhesion of primary MCL cells. Chang B Y et al. Blood 2013;122:2412-2424 ©2013 by American Society of Hematology
Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):
Ibrutinib (PCI-32765) First-In-Class BTK Inhibitor IM Los Angeles 18 Jan
Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.
Inhibition of NF-κB induces apoptosis of KSHV-infected primary effusion lymphoma cells by Shannon A. Keller, Elaine J. Schattner, and Ethel Cesarman Blood.
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.
The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse.
Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes.
Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B- cell lymphomas by Lingchen Fu, Yen-Chiu Lin-Lee,
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,
CLL Stromal cell protect Conventional therapies Versteckspiel im Wald by Friedrich Eduard Meyerheim ( ) The “outside” (microenvironment) of the.
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma by Salvia Jain, Dina Stroopinsky, Li Yin, Jacalyn Rosenblatt, Maroof Alam, Parul.
Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory.
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
SAP mediates specific cytotoxic T-cell functions in X- linked lymphoproliferative disease by Reza Sharifi, Joanna C. Sinclair, Kimberly C. Gilmour, Peter.
Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.
The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase–dependent cleavage of calreticulin in AML patients by Sarah Mans, Yara Banz,
Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.
Ibrutinib: First-in Class Inhibitor of BTK Forms a specific and irreversible bond with cysteine-481 in BTK Highly potent BTK inhibition at IC 50 =
Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience.
Alternative activation of macrophages by IL-4 impairs phagocytosis of pathogens but potentiates microbial- induced signalling and cytokine secretion by.
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs) by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Activity and Tolerability of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis by Katharine H.
Blockade of osteopontin reduces alloreactive CD8 + T cell– mediated graft-versus-host disease by Fang Zhao, Yi Zhang, Hao Wang, Min Jin, Shan He, Yufang.
Prevention of graft-versus-host disease by anti–IL-7Rα antibody by Brile Chung, Eric P. Dudl, Dullei Min, Lora Barsky, Nancy Smiley, and Kenneth I. Weinberg.
Synchronized integrin engagement and chemokine activation is crucial in neutrophil extracellular trap– mediated sterile inflammation by Jan Rossaint, Jan.
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL by Arian.
Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones,
Presented by Jeremy Smirnov. BCR and LFA-1 Induce B Cell Spreading Cell Spreading - a change in morphology that allows the B cell to “search” for antigens.
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways.
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.
IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Rα in T cells by Catarina M. Henriques, José Rino, Robert J.
Manipulating the onset of cell cycle withdrawal in differentiated erythroid cells with cyclin-dependent kinases and inhibitors by Igor Matushansky, Farshid.
Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de.
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies by Jutta Deckert, Peter U. Park,
A Prospective Multicenter Study of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib in Patients with Relapsed or Refractory Waldenstrom’s Macroglobulinemia.
Siglec-E is a negative regulator of acute pulmonary neutrophil inflammation and suppresses CD11b β2- integrin–dependent signaling by Sarah J. McMillan,
Disease-associated missense mutations in the EVH1 domain disrupt intrinsic WASp function causing dysregulated actin dynamics and impaired dendritic cell.
MicroRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia by Daniela Asslaber, Josefina.
Targeting the Cell Cycle in Lymphoma Therapy Selina Chen-Kiang Weill Cornell Medical College.
How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.
Sonic hedgehog mediates a novel pathway of PDGF-BB– dependent vessel maturation by Qinyu Yao, Marie-Ange Renault, Candice Chapouly, Soizic Vandierdonck,
Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production by Hélène Gary-Gouy, Julie Harriague, Georges Bismuth, Cornelia Platzer,
Formation of human hepatocytes by human hematopoietic stem cells in sheep by Graça Almeida-Porada, Christopher D. Porada, Jason Chamberlain, Ali Torabi,
The Bruton’s Tyrosine Kinase Inhibitor PCI is Highly Active as Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary.
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,
Immune regulatory activity of CD34 + progenitor cells: evidence for a deletion-based mechanism mediated by TNF-α by Hilit Gur, Rita Krauthgamer, Esther.
HOXA9 is required for survival in human MLL-rearranged acute leukemias by Joerg Faber, Andrei V. Krivtsov, Matthew C. Stubbs, Renee Wright, Tina N. Davis,
EBV-positive diffuse large B-cell lymphoma of the elderly by Chi Young Ok, Thomas G. Papathomas, L. Jeffrey Medeiros, and Ken H. Young Blood Volume 122(3):
© 2017 SlidePlayer.com Inc. All rights reserved.